Eiken Chemical Co Ltd <4549.T> :Says it signs overseas (China, Korea, Taiwan and Thailand excluded) sales contract with HUMAN (HUMAN Gesellschaft fuer Biochemica und Diagnostica mbH, a germany firm) for tuberculosis genetic testing drugs and devices using the LAMP included two kinds of method.
EIKEN CHEMICAL CO LTD:Enters business alliance with Sysmex Corporation, in the field of urine chemistry testing in overseas markets.
EIKEN CHEMICAL CO LTD:Says the company lowered the consolidated mid-year outlook for revenue to 15,819 million yen from 15,970 million yen for the FY ending March 2015.Operating profit forecast increased to 1,855 million yen from 1,570 million yen.Ordinary profit forecast increased to 1,955 million yen from 1,600 million yen.Net profit forecast increased to 1,349 million yen from 1,010 million yen.Earnings per share increased to 74.05 yen from 55.52 yen.Comments the research and development expense, the decreased corporate tax and increased income are the main reasons for the forecast.
EIKEN CHEMICAL CO LTD:To issue a year-end dividend of 20 yen per share to all the shareholders of record as of March 31, for the fiscal year ended March 2014.Payment date June 3.Says latest dividend forecast was 15 yen per share.
EIKEN CHEMICAL CO LTD:Says appointed Tetsuya Teramoto as chairman of the board to replace Tadao Kurozumi, effective June.Says appointed Morifumi Wada to replace Tetsuya Teramoto as president of the company, effective June.
EIKEN CHEMICAL CO LTD announced that it has decided to issue a year-end dividend payment of JPY 20 per share (JPY 363 million in total), above its latest dividend forecast of JPY 15 per share announced on January 30, 2013, to all its shareholders as a record of March 31, 2013. The dividend will be paid on June 4, 2013.
EIKEN CHEMICAL CO LTD announced that it has raised its consolidated full-year outlook for revenue from JPY 28,500 million to JPY 28,645 million, ordinary profit from JPY 2,730 million to JPY 2,812 million, net profit from JPY 1,700 million to JPY 2,453 million and earning per share from JPY 93.52 to JPY 134.98, but lowered the outlook for operating profit from JPY 2,580 million to JPY 2,548 million, for the fiscal year ended March 2013. The Company raised the outlook due to the record of JPY 991 million extraordinary profit on the selling of land, among others.
EIKEN CHEMICAL CO LTD announced that it has decided to sell a Tokyo-based property, which was acquired on December 22, 2010, at the price of JPY 4,500 million on March 21, 2013. As a result, the Company expects the extraordinary profit of approximately JPY 1 billion, for the fiscal year ending March 2013.
Eiken Chemical Co., Ltd. announced that it will issue dividend of JPY 18.00 per share, or JPY 326 million in total, effective June 6, 2012, up from a forecast of JPY 13.00 per share announced on January 27, 2012, from retained earnings to shareholders as of March 31, 2012.
Eiken Chemical Co., Ltd. announced that it has raised its consolidated full-year outlook for revenue from JPY 27,610 million to JPY 27,702 million, operating profit from JPY 2,210 million to JPY 2,363 million, ordinary profit from JPY 2,280 million to JPY 2,543 million, net profit from JPY 1,080 million to JPY 1,460 million and earning per share from JPY 59.45 to JPY 80.38, for the fiscal year ended March 2012. This is due to the cost reduction as well as the record of JPY 117 million extraordinary profit on the selling of business office, among others. According to I/B/E/S Estimates, analysts were expecting the Company to report full-year revenue of JPY 27.76 billion and net profit of JPY 1.27 billion.